A Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase II Study to Assess the Opioid-Sparing Activity of PAX-1 in Patients with Persistent Cancer Pain.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs PAX 1 001 (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Komipharm International
- 04 Sep 2018 Planned initiation date changed from 3 Sep 2018 to 28 Sep 2018.
- 13 Aug 2018 New trial record